search
Back to results

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL)

Primary Purpose

Chronic Lymphocytic Leukemia

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Obinutuzumab
Ublituximab
TGR-1202
Chlorambucil
Sponsored by
TG Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Lymphocytic Leukemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Treatment naïve or previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment
  • Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
  • Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
  • Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
  • Prior therapy with obinutuzumab and/or chlorambucil or a PI3K delta inhibitor

Sites / Locations

  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Experimental

Arm Label

Ublituximab + TGR-1202

Obinutuzumab + Chlorambucil

Ublituximab

TGR-1202

Arm Description

Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions TGR-1202: Fixed oral daily dose

Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6 Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6

- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions

- TGR-1202: Fixed oral daily dose

Outcomes

Primary Outcome Measures

Progression-Free Survival
To assess the progression-free survival (PFS) in patients with Chronic Lymphocytic Leukemia treated with ublituximab in combination with TGR-1202 compared to obinutuzumab + chlorambucil

Secondary Outcome Measures

Overall Response Rate
To assess the overall response rate (ORR) in patients with Chronic Lymphocytic Leukemia treated with ublituximab + TGR-1202 compared to ublituximab and TGR-1202 alone

Full Information

First Posted
November 18, 2015
Last Updated
July 19, 2023
Sponsor
TG Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02612311
Brief Title
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Acronym
UNITY-CLL
Official Title
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
November 19, 2015 (Actual)
Primary Completion Date
February 22, 2023 (Actual)
Study Completion Date
February 22, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TG Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Lymphocytic Leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
603 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ublituximab + TGR-1202
Arm Type
Experimental
Arm Description
Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions TGR-1202: Fixed oral daily dose
Arm Title
Obinutuzumab + Chlorambucil
Arm Type
Active Comparator
Arm Description
Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6 Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6
Arm Title
Ublituximab
Arm Type
Experimental
Arm Description
- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
Arm Title
TGR-1202
Arm Type
Experimental
Arm Description
- TGR-1202: Fixed oral daily dose
Intervention Type
Biological
Intervention Name(s)
Obinutuzumab
Other Intervention Name(s)
GAZYVA
Intervention Description
Obinutuzumab: IV infusion
Intervention Type
Biological
Intervention Name(s)
Ublituximab
Intervention Description
Ublituximab: IV infusion
Intervention Type
Drug
Intervention Name(s)
TGR-1202
Intervention Description
TGR-1202: Oral daily dose
Intervention Type
Drug
Intervention Name(s)
Chlorambucil
Other Intervention Name(s)
Leukeran
Intervention Description
Chlorambucil: Oral dose
Primary Outcome Measure Information:
Title
Progression-Free Survival
Description
To assess the progression-free survival (PFS) in patients with Chronic Lymphocytic Leukemia treated with ublituximab in combination with TGR-1202 compared to obinutuzumab + chlorambucil
Time Frame
From date of randomization until the date of first documented progression, assessed up through 3 years
Secondary Outcome Measure Information:
Title
Overall Response Rate
Description
To assess the overall response rate (ORR) in patients with Chronic Lymphocytic Leukemia treated with ublituximab + TGR-1202 compared to ublituximab and TGR-1202 alone
Time Frame
Every 12 weeks up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Treatment naïve or previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Exclusion Criteria: Any major surgery, chemotherapy or immunotherapy within the last 21 days Evidence of hepatitis B virus, hepatitis C virus or known HIV infection Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation) Prior therapy with obinutuzumab and/or chlorambucil or a PI3K delta inhibitor
Facility Information:
Facility Name
TG Therapeutics Investigational Trial Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35805
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36604
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85016
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85711
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Fayetteville
State/Province
Arkansas
ZIP/Postal Code
72703
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Concord
State/Province
California
ZIP/Postal Code
94520
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Greenbrae
State/Province
California
ZIP/Postal Code
94904
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Pismo Beach
State/Province
California
ZIP/Postal Code
93449
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Pleasanton
State/Province
California
ZIP/Postal Code
94588
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93105
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Whittier
State/Province
California
ZIP/Postal Code
90603
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80012
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Bridgeport
State/Province
Connecticut
ZIP/Postal Code
06606
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06904
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Newark
State/Province
Delaware
ZIP/Postal Code
19713
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33916
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32204
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Ocala
State/Province
Florida
ZIP/Postal Code
34471
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Pensacola
State/Province
Florida
ZIP/Postal Code
32504
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Tallahassee
State/Province
Florida
ZIP/Postal Code
32308
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33407
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Albany
State/Province
Georgia
ZIP/Postal Code
31701
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Decatur
State/Province
Illinois
ZIP/Postal Code
62526
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Niles
State/Province
Illinois
ZIP/Postal Code
60714
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Peoria
State/Province
Illinois
ZIP/Postal Code
61615
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Swansea
State/Province
Illinois
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Urbana
State/Province
Illinois
ZIP/Postal Code
61801
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46804
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46237
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Ames
State/Province
Iowa
ZIP/Postal Code
50010
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Cedar Rapids
State/Province
Iowa
ZIP/Postal Code
52403
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
64132
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Westwood
State/Province
Kansas
ZIP/Postal Code
66210
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21202
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21215
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21044
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01608
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Jackson
State/Province
Michigan
ZIP/Postal Code
49201
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Saint Louis Park
State/Province
Minnesota
ZIP/Postal Code
55416
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65212
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68510
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07962
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Somerville
State/Province
New Jersey
ZIP/Postal Code
00876
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
East Setauket
State/Province
New York
ZIP/Postal Code
11733
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Glens Falls
State/Province
New York
ZIP/Postal Code
12801
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Durham
State/Province
North Carolina
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Hickory
State/Province
North Carolina
ZIP/Postal Code
28602
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Kinston
State/Province
North Carolina
ZIP/Postal Code
28501
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Washington
State/Province
North Carolina
ZIP/Postal Code
27889
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45236
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43623
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97227
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Springfield
State/Province
Oregon
ZIP/Postal Code
97477
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Camp Hill
State/Province
Pennsylvania
ZIP/Postal Code
17011
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Danville
State/Province
Pennsylvania
ZIP/Postal Code
17822
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19106
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Pawtucket
State/Province
Rhode Island
ZIP/Postal Code
00286
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57105
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Watertown
State/Province
South Dakota
ZIP/Postal Code
57201
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Bedford
State/Province
Texas
ZIP/Postal Code
76022
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78217
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Tyler
State/Province
Texas
ZIP/Postal Code
75702
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Ogden
State/Province
Utah
ZIP/Postal Code
84405
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Blacksburg
State/Province
Virginia
ZIP/Postal Code
24060
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Fort Belvoir
State/Province
Virginia
ZIP/Postal Code
22060
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Olympia
State/Province
Washington
ZIP/Postal Code
98502
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Spokane
State/Province
Washington
ZIP/Postal Code
99216
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Vancouver
State/Province
Washington
ZIP/Postal Code
98684
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Yakima
State/Province
Washington
ZIP/Postal Code
98902
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Wauwatosa
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Ashkelon
Country
Israel
Facility Name
TG Therapeutics Investigational Trial Site
City
Be'er Sheva
Country
Israel
Facility Name
TG Therapeutics Investigational Trial Site
City
Haifa
Country
Israel
Facility Name
TG Therapeutics Investigational Trial Site
City
Jerusalem
Country
Israel
Facility Name
TG Therapeutics Investigational Trial Site
City
Nahariya
Country
Israel
Facility Name
TG Therapeutics Investigational Trial Site
City
Petah tikva
Country
Israel
Facility Name
TG Therapeutics Investigational Trial Site
City
Tel Aviv
Country
Israel
Facility Name
TG Therapeutics Investigational Trial Site
City
Bologna
Country
Italy
Facility Name
TG Therapeutics Investigational Trial Site
City
Ferrara
Country
Italy
Facility Name
TG Therapeutics Investigational Trial Site
City
Milan
Country
Italy
Facility Name
TG Therapeutics Investigational Trial Site
City
Rome
Country
Italy
Facility Name
TG Therapeutics Investigational Trial Site
City
Torino
Country
Italy
Facility Name
TG Therapeutics Investigational Trial Site
City
Chorzów
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Gdynia
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Krakow
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Lublin
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Słupsk
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Warszawa
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Wroclaw
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Łódź
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Krasnozatonskiy
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Moscow
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Perm
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Petrozavodsk
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Rodionova
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Saint Petersburg
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Smolensk
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Tula
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Yaroslavl
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Barcelona
Country
Spain
Facility Name
TG Therapeutics Investigational Trial Site
City
Madrid
Country
Spain
Facility Name
TG Therapeutics Investigational Trial Site
City
Valencia
Country
Spain
Facility Name
TG Therapeutics Investigational Trial Site
City
Cambridge
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Cumbria
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Dudley West
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
London
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Northbrook
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Northumbria
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Norwich
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Peterborough
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Southampton
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
St. James
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Sunderland
Country
United Kingdom
Facility Name
TG Therapeutics Investigational Trial Site
City
Wolverhampton
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia

We'll reach out to this number within 24 hrs